RareCan

RareCan

RareCan aims to accelerate research and ultimately improve treatments and outcomes for people with rare cancers.

Founded 2019

United Kingdom 8 employees Equity Crowdfunding Total: $576.88K Biotechnology, Health Care

RareCan is a United Kingdom-based biotechnology and healthcare company, founded in 2019, with a mission to accelerate research and improve treatments for individuals with rare cancers. The company has recently secured a £374.88K Equity Crowdfunding investment on 15 June 2022 through Crowdcube. RareCan addresses the pressing need for rapid access to consenting patients, secure data, and bio-samples for researchers working on rare cancers. The company's innovative platform connects consenting patients with leading researchers, creating a large and growing patient community with a BioResource. This provides researchers with access to tissue and blood samples, as well as genetic data, thereby reducing the time taken to provide samples for research purposes from months to weeks. One of RareCan's key strengths lies in its ability to build precise cohorts of trial participants, enabling the delivery of histology-independent trials targeting genetic mutations common across different rare cancer types. This positions RareCan at the forefront of advancing clinical research into rare cancers. Supported by a network of NHS Trusts and patient organizations, including GIST Cancer UK, RareCan is uniquely positioned as the first and only company in the market to integrate 'consent to contact' patient recruitment, abundant data for accurate screening, and access to bio-samples and genetics. This places RareCan at the forefront of driving progress in clinical research, making it a compelling investment opportunity for venture capitalists seeking to support breakthrough innovations in the biotechnology and healthcare industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Equity Crowdfunding	£374.88K	1	Crowdcube	15 Jun 2022
Seed Round	£200.00K	1	Mandashi	23 Mar 2021
Grant	£2.00K	1	Innovation SuperNetwork	01 Jan 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Equity Crowdfunding

£374.88K

Crowdcube

15 Jun 2022

Seed Round

£200.00K

Mandashi

23 Mar 2021

Grant

£2.00K

Innovation SuperNetwork

01 Jan 2021

FAQ About RareCan

RareCan aims to accelerate research and ultimately improve treatments and outcomes for people with rare cancers.

RareCan was founded in 2019.

RareCan is headquartered in United Kingdom.

RareCan operates in Biotechnology and Health Care. Its work centres on rare cancers, clinical trials, patient recruitment and research acceleration.

RareCan has approximately 8 employees.

RareCan has completed 3 funding rounds, raising a total of $576.88K. The latest funding stage is Equity Crowdfunding.

Top alternatives and competitors to RareCan include Perlegen Sciences, Precision For Medicine, Sano Genetics, H1, Photolitec LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

RareCan and Perlegen Sciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About RareCan

Funding Rounds & Investors (3)

RareCan Alternatives & Competitors

FAQ About RareCan